Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 54

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 54
---
 Carrying ValueForeign Currency AdjustmentsAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful LivesDeveloped technologies$590,000 $— $(227,574)$362,426 10 years, 5 monthsCustomer relationships90 — (56)34 10 yearsTotal finite-lived intangible assets, net590,090 — (227,630)362,460 Acquired IPR&D57,366 2,737 — 60,103      Total intangible assets, net$647,456 $2,737 $(227,630)$422,563 December 31, 2024Gross Carrying ValueAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful LivesDeveloped technologies$590,000 $(198,934)$391,066 10 years, 5 monthsCustomer relationships90 (52)38 10 years     Total finite-lived intangible assets, net590,090 (198,986)391,104 Acquired IPR&D34,866 — 34,866      Total intangible assets, net$624,956 $(198,986)$425,970 

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 18

Amortization expense on intangible assets was $14.3 million for both the three months ended June 30, 2025 and 2024. Amortization expense on intangible assets was $28.6 million for both the six months ended June 30, 2025 and 2024.Assuming no changes in the gross carrying amount of these intangible assets, the future estimated amortization expense on the finite-lived intangible assets will be $28.6 million for the remaining six months of 2025, $57.3 million each year from 2026 to 2030, $37.4 million in 2031, $7.9 million in 2032 and $2.2 million in 2033.

NOTE 9—DEBT

The carrying value of the Company’s outstanding debt is summarized as follows (in thousands):June 30,December 31,20252024Term loan A facility maturing March 2028 (1)$97,828 $104,211 2.125% Convertible senior notes due May